{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:11:58Z","timestamp":1771949518675,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.clml.2022.04.006","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T10:48:28Z","timestamp":1649414908000},"page":"e738-e744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed\/Refractory Diffuse Large B-cell Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Mehdi","family":"Hamadani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo F","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.04.006_bib0001","unstructured":"American Cancer Society. Types of B-cell lymphoma. Accessed at: December 21, 2020. Accessed from: https:\/\/www.cancer.org\/cancer\/non-hodgkin-lymphoma\/about\/b-cell-lymphoma.html"},{"key":"10.1016\/j.clml.2022.04.006_bib0002","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.006_bib0003","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clml.2022.04.006_bib0004","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.006_bib0005","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2022.04.006_bib0006","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.006_bib0007","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"International Non-Hodgkin\u2019s lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"Shipp","year":"1993","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.clml.2022.04.006_bib0008","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.clml.2022.04.006_bib0009","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235786","article-title":"Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma","volume":"15","author":"Terziev","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2022.04.006_bib0011","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.006_bib0012","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.006_bib0013","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2022.04.006_bib0014","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study","volume":"52","author":"Van Den Neste","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.clml.2022.04.006_bib0015","series-title":"NCCN Clinical Practice Guidelines in Oncology - B-cell Lymphomas (Version 4.2020)","article-title":"National comprehensive cancer network","year":"2020"},{"key":"10.1016\/j.clml.2022.04.006_bib0016","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","article-title":"Management of relapsed\/refractory DLBCL","volume":"31","author":"Sarkozy","year":"2018","journal-title":"Best Pract Res Clin Haematol."},{"key":"10.1016\/j.clml.2022.04.006_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2022.04.006_bib0018","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.006_bib0019","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-021-01097-z","article-title":"Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress","volume":"14","author":"Chu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2022.04.006_bib0020","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.04.006_bib0021","unstructured":"United States Food and Drug Administration (FDA). FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma. 2021. Accessed on February 17, 2021. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma"},{"key":"10.1016\/j.clml.2022.04.006_bib0022","unstructured":"United States Food and Drug Administration (FDA). Highlights of prescribing information: KYMRIAH (tisagenlecleucel) suspension for intravenous infusion. 2021. Accessed on May 7, 2021. Available from: https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/kymriah.pdf"},{"key":"10.1016\/j.clml.2022.04.006_bib0023","unstructured":"United States Food and Drug Administration (FDA). Highlights of prescribing information: POLIVY (polatuzumab vedotin-piiq) for injection, for intravenous use. 2021. Accessed on February 17, 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121Orig1s003lbl.pdf"},{"key":"10.1016\/j.clml.2022.04.006_bib0024","unstructured":"United States Food and Drug Administration (FDA). Highlights of prescribing information: YESCARTA (axicabtagene ciloleucel) suspension for intravenous infusion. 2021. Accessed on September 23, 2021. Available from: https:\/\/www.fda.gov\/media\/108377\/download"},{"key":"10.1016\/j.clml.2022.04.006_bib0025","unstructured":"United States Food and Drug Administration (FDA). Highlights of prescribing information: ZYNLONTA\u2122 (loncastuximab tesirine-lpyl) for injection, for intravenous use. 2021. Accessed on September 23, 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761196s000lbl.pdf"},{"key":"10.1016\/j.clml.2022.04.006_bib0026","unstructured":"United States Food and Drug Administration (FDA). Highlights of prescribing information: MONJUVI\u00ae (tafasitamab-cxix) for injection, for intravenous use. 2021. Accessed on September 23, 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761163s000lbl.pdf"},{"key":"10.1016\/j.clml.2022.04.006_bib0027","first-page":"1","article-title":"Characteristics and treatment patterns of relapsed\/refractory diffuse large B-cell lymphoma in patients receiving >\/=3 therapy lines in post-CAR-T era","author":"Xie","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2022.04.006_bib0028","series-title":"A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","author":"ADC Therapeutics","year":"2020"},{"key":"10.1016\/j.clml.2022.04.006_bib0029","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.04.006_bib0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0266462319000333","article-title":"Population adjustment methods for indirect comparisons: a review of National institute for health and care excellence technology appraisals","volume":"35","author":"Phillippo","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.clml.2022.04.006_bib0031","series-title":"Technical Support Document 18: Methods for Population-Adjusted Indirect Comparisons in Submissions to NICE. (Technical Support Documents)","author":"Phillippo","year":"2016"},{"key":"10.1016\/j.clml.2022.04.006_bib0032","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clml.2022.04.006_bib0033","doi-asserted-by":"crossref","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et\u00a0al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940-7. doi:10.1016\/j.jval.2012.05.004","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"10.1016\/j.clml.2022.04.006_bib0034","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clml.2022.04.006_bib0035","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.006_bib0036","first-page":"5","article-title":"Staging and response assessment in lymphomas: the new Lugano classification","volume":"4","author":"Cheson","year":"2015","journal-title":"Chin Clin Oncol."},{"key":"10.1016\/j.clml.2022.04.006_bib0037","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/sj.ki.5002648","article-title":"Bias in clinical research","volume":"73","author":"Tripepi","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.clml.2022.04.006_bib0038","article-title":"Autologous transplant versus chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission","author":"Shadman","year":"2021","journal-title":"Blood."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:05Z","timestamp":1761871265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022001173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2152265022001173"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed\/Refractory Diffuse Large B-cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}